search
Back to results

Cerebrospinal Fluid Proteome in Hydrocephalus (PROLIPHYC)

Primary Purpose

Normal Pressure Hydrocephalus

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
patient CSF extraction with hydrocephalus
witness CSF extraction
Sponsored by
University Hospital, Toulouse
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Normal Pressure Hydrocephalus focused on measuring hydrocephalus, proteomic, cerebrospinal fluid

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Gait problems, cognitive decline, urinary incontinence and enlarged ventricles on imaging

Exclusion Criteria:

  • Psychiatric disorders
  • Lumbar punction contraindication
  • RMI contraindication

Sites / Locations

  • Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

patient

witness

Arm Description

patient CSF extraction with hydrocephalus

patient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.

Outcomes

Primary Outcome Measures

CSF proteome measure
CSF extraction (3 ml)

Secondary Outcome Measures

correlation between CSF proteome and gait analysis
compare results from CSF proteome and gait analysis
correlation between CSF proteome and MRI brain imaging
compare results from CSF proteome and brain imaging

Full Information

First Posted
June 18, 2013
Last Updated
November 9, 2020
Sponsor
University Hospital, Toulouse
search

1. Study Identification

Unique Protocol Identification Number
NCT02016352
Brief Title
Cerebrospinal Fluid Proteome in Hydrocephalus
Acronym
PROLIPHYC
Official Title
Cerebrospinal Fluid Proteome in Hydrocephalus
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
September 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
PROLIPHYC is a collaborative prospective study that aims at discovering deep cerebrospinal fluid (CSF) proteome with a new clinically-compatible proteomics strategy, in a cohort of 100 patients suspected of neurodegenerative diseases and/or normal pressure hydrocephalus.
Detailed Description
CSF proteome is the real time protein content that may reveal useful biomarkers for diagnosis and therapeutic decision-making. But the low protein concentration in CSF and the low volumes typically obtained after lumbar puncture precludes the conventional use of proteomic analysis. We miniaturized the method to be compatible with low-volume samples by combination of nanoLC-MS/MS analysis and combinatorial peptide ligand library technology to reduce the dynamic range of protein concentration in CSF and unmask previously undetected proteins. We demonstrated that this deep proteomic analysis allows profiling the CSF proteome with a reasonable depth, in short analytical times and good accuracy. We settled a clinically-compatible proteomics strategy targeting the deep CSF proteome discovery. The PROLIPHYC study is a prospective study that aims at analysing CSF proteome with our new strategy in a cohort of patients suspected of normal pressure hydrocephalus and/or related neurodegenerative diseases. The PROLIPHYC project combines detailed clinical and neuropsychological evaluation, gait analysis, MRI brain imaging, lumbar CSF dynamics and deep proteome. We hypothesize in the PROLIPHYC study that a specific cluster of polypeptides can be associated with Alzheimer disease, vascular dementia and normal pressure hydrocephalus profiles. Validating this hypothesis might be a significant step towards a proteomic lexicon of aging brain, neurodegenerative diseases and dementia. Neurosciences department and Alzheimer disease centre from the Toulouse University Hospital are both involved in this project. The deep proteomic study is performed in Toulouse by the Institute of Pharmacology and Structural Biology with the academic support of the Institute of Mathematics of Toulouse.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Normal Pressure Hydrocephalus
Keywords
hydrocephalus, proteomic, cerebrospinal fluid

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
patient
Arm Type
Experimental
Arm Description
patient CSF extraction with hydrocephalus
Arm Title
witness
Arm Type
Other
Arm Description
patient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.
Intervention Type
Biological
Intervention Name(s)
patient CSF extraction with hydrocephalus
Intervention Description
CSF extraction
Intervention Type
Biological
Intervention Name(s)
witness CSF extraction
Intervention Description
CSF extraction from patient not suffering from hydrocephalus
Primary Outcome Measure Information:
Title
CSF proteome measure
Description
CSF extraction (3 ml)
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
correlation between CSF proteome and gait analysis
Description
compare results from CSF proteome and gait analysis
Time Frame
72 hours
Title
correlation between CSF proteome and MRI brain imaging
Description
compare results from CSF proteome and brain imaging
Time Frame
72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Gait problems, cognitive decline, urinary incontinence and enlarged ventricles on imaging Exclusion Criteria: Psychiatric disorders Lumbar punction contraindication RMI contraindication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric SCHMIDT, MD PhD
Organizational Affiliation
University Hospital, Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital
City
Toulouse
ZIP/Postal Code
31059
Country
France

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
17012342
Citation
Bech-Azeddine R, Hogh P, Juhler M, Gjerris F, Waldemar G. Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting. J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):157-61. doi: 10.1136/jnnp.2006.095117. Epub 2006 Sep 29.
Results Reference
background

Learn more about this trial

Cerebrospinal Fluid Proteome in Hydrocephalus

We'll reach out to this number within 24 hrs